国家药监局：我国医药产业规模位居全球第二位

Core Insights - The National Medical Products Administration (NMPA) has approved 204 innovative drugs and 265 innovative medical devices since the beginning of the 14th Five-Year Plan, with 50 innovative drugs and 49 innovative medical devices approved in the first seven months of this year [1][2] - China's pharmaceutical industry ranks second globally, with approximately 30% of innovative drugs under research worldwide [1][2] Group 1: Drug Safety and Regulation - The NMPA emphasizes the importance of drug quality and safety, implementing dynamic supervision throughout the drug lifecycle and establishing a risk consultation mechanism [1] - Special actions have been taken to enhance drug safety, including annual sampling of over 200,000 batches of various drugs and 20,000 batches of medical devices [1] Group 2: Support for Pharmaceutical Development - The NMPA has reformed the review and approval system, introducing four expedited channels for breakthrough therapies and prioritizing certain products for faster approval [2] - The approval of traditional Chinese medicine (TCM) has also increased, with 27 innovative TCM drugs approved during the 14th Five-Year Plan [2] Group 3: Meeting Public Health Needs - The NMPA has optimized the review process for urgently needed foreign drugs, allowing patients to access the latest global drug developments more quickly [2] - A total of 387 pediatric drugs and 147 rare disease drugs have been approved since the start of the 14th Five-Year Plan, addressing the needs of key populations [2]